Table 1.
Patient Comorbidities and Medication Use
| Case (n = 49) | Control (n = 49) | P Value | |
|---|---|---|---|
| Median LVEF | 45.0% (27.5%-49.0%) | 60.0% (50.0%-69.0%) | <.01 |
| Anthracycline dose, median (mg/m2) | 220.0 (.0-800.0) | 216.0 (.0-580.0) | .24 |
| CAD | 6 (12.2%) | 1 (2.0%) | .05 |
| Arrhythmia | 3 (6.1%) | 0 | .08 |
| CHF | 5 (10.2%) | 1 (2.0%) | .09 |
| Diabetes mellitus | 8 (16.3%) | 3 (6.1%) | .11 |
| COPD | 1 (2.0%) | 0 | .31 |
| CKD | 7 (14.3%) | 3 (6.1%) | .19 |
| Hypertension | 9 (18.4%) | 7 (14.3%) | .58 |
| Dyslipidemia | 8 (16.3%) | 5 (10.2%) | .37 |
| Prior MI | 3 (6.1%) | 0 | .08 |
| ACE inhibitor | 15 (30.6%) | 3 (6.1%) | <.01 |
| ARB | 3 (6.1%) | 1 (2.0%) | .31 |
| Beta blocker | 16 (32.7%) | 2 (4.1%) | <.01 |
| Aspirin | 6 (12.2%) | 0 | .01 |
| Clopidogrel | 2 (4.1%) | 0 | .15 |
| Statin | 9 (18.4%) | 2 (4.1%) | .03 |
| Loop diuretic | 4 (8.2%) | 1 (2.0%) | .17 |
COPD indicates chronic obstructive pulmonary disease; CKD, chronic kidney disease; ARB, angiotensin receptor blocker.
Data presented are n (%) unless otherwise indicated.